Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-natal development of factor IX

F Schettini, D De Mattia, M Altomare

    Acta Paediatrica Scandinavica
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Standardized handover improves trauma team communication: evidence from a level I Trauma Center in Italy.

    Updates in surgery·2026
    Same author

    Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

    ESMO real world data and digital oncology·2026
    Same author

    Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

    ESMO open·2026
    Same author

    Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

    ESMO open·2025
    Same author

    Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.

    ESMO open·2025
    Same author

    A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults.

    Beneficial microbes·2025
    Same journal

    Atrial natriuretic peptide and renin-aldosterone relationship in healthy newborn infants.

    Acta paediatrica Scandinavica·1991
    Same journal

    Adult panhypopituritarism presenting as idiopathic growth hormone deficiency in childhood: really idiopathic?

    Acta paediatrica Scandinavica·1991
    Same journal

    Growth hormone therapy and final height in girls with Turner's syndrome.

    Acta paediatrica Scandinavica·1991
    Same journal

    Mineral metabolism in obese children.

    Acta paediatrica Scandinavica·1991
    Same journal

    Sex differences in vulnerability?

    Acta paediatrica Scandinavica·1991
    Same journal

    Idiopathic dilatation of the aorta with dissection in a family without Marfan syndrome.

    Acta paediatrica Scandinavica·1991
    See all related articles

    Newborns have low Factor IX clotting activity and antigen levels, which increase in the first three days of life. Oral vitamin K1 did not significantly alter these levels in healthy, breastfed infants.

    Area of Science:

    • Biochemistry
    • Pediatrics
    • Hematology

    Background:

    • Factor IX is crucial for blood coagulation.
    • Newborns typically present with lower levels of vitamin K-dependent clotting factors.

    Purpose of the Study:

    • To evaluate the postnatal development of Factor IX clotting activity and antigen levels in healthy, breastfed newborns.
    • To assess the impact of oral vitamin K1 administration on these levels.

    Main Methods:

    • Studied 111 healthy, breastfed infants aged 1-30 days.
    • Measured Factor IX clotting activity using a one-stage assay.
    • Quantified Factor IX antigen levels via electroimmunoassay.

    Main Results:

    • Factor IX clotting activity and antigen levels were low on day 1, increasing significantly within the first three days.

    Related Experiment Videos

  • Levels remained stable post-day 3 and were lower than adult values throughout the first month.
  • Oral vitamin K1 administration showed no significant difference in Factor IX activity.

    • Conclusions:

    • Factor IX levels in newborns undergo rapid postnatal development in the initial days of life.
    • Oral vitamin K1 did not demonstrate a significant impact on Factor IX levels in this cohort.
    • Newborns exhibit distinct Factor IX profiles compared to adults, normalizing over the first month.